

Aitziber Buquã©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6079886/publications.pdf>

Version: 2024-02-01

59
papers

7,328
citations

186209

28
h-index

197736

49
g-index

61
all docs

61
docs citations

61
times ranked

11897
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , 2017, 17, 97-111.	10.6	2,000
2	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. <i>Cancer Cell</i> , 2015, 28, 690-714.	7.7	1,205
3	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741.	12.5	701
4	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
5	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	7.7	410
6	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
7	Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. <i>Nature Immunology</i> , 2020, 21, 1160-1171.	7.0	214
8	Immunomodulation by targeted anticancer agents. <i>Cancer Cell</i> , 2021, 39, 310-345.	7.7	131
9	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1088631.	2.1	104
10	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1008814.	2.1	102
11	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411.	2.1	97
12	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1655964.	2.1	97
13	eIF2 γ phosphorylation as a biomarker of immunogenic cell death. <i>Seminars in Cancer Biology</i> , 2015, 33, 86-92.	4.3	95
14	Trial Watch: Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740.	2.1	88
15	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	2.8	82
16	PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. <i>Oncolmmunology</i> , 2020, 9, 1721810.	2.1	79
17	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	5.8	71
18	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmmunology</i> , 2016, 5, e1214790.	2.1	64

#	ARTICLE	IF	CITATIONS
19	Modeling Tumor Immunology and Immunotherapy in Mice. <i>Trends in Cancer</i> , 2018, 4, 599-601.	3.8	63
20	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 440-462.	21.5	58
21	Trial Watch: Immunostimulation with cytokines in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1115942.	2.1	52
22	The ratio of CD8 ⁺ /FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i> . <i>Oncolmmunology</i> , 2016, 5, e1218106.	2.1	50
23	Trial Watch: Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1149674.	2.1	46
24	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1855-1863.	3.2	41
25	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolmmunology</i> , 2018, 7, e1433982.	2.1	38
26	Anticancer effects of anti-CD47 immunotherapy <i>in vivo</i> . <i>Oncolmmunology</i> , 2019, 8, 1550619.	2.1	32
27	Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells. <i>Molecular Cancer</i> , 2012, 11, 25.	7.9	30
28	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. <i>Oncolmmunology</i> , 2021, 10, 1962592.	2.1	30
29	Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1046673.	2.1	29
30	Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells. <i>PLoS ONE</i> , 2013, 8, e63338.	1.1	28
31	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	2.1	26
32	Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. <i>Clinical and Translational Oncology</i> , 2014, 16, 339-350.	1.2	24
33	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1139275.	2.1	21
34	Estrogen Receptor 1 Gene Expression and Its Combination with Estrogen Receptor 2 or Aromatase Expression Predicts Survival in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e109659.	1.1	20
35	Apoptotic caspases cut down the immunogenicity of radiation. <i>Oncolmmunology</i> , 2019, 8, e1655364.	2.1	19
36	Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. <i>Cancer Letters</i> , 2015, 368, 26-35.	3.2	15

#	ARTICLE	IF	CITATIONS
37	Immunosuppressive cell death in cancer. <i>Nature Reviews Immunology</i> , 2017, 17, 402-402.	10.6	13
38	Morphometric analysis of immunoselection against hyperploid cancer cells. <i>Oncotarget</i> , 2015, 6, 41204-41215.	0.8	13
39	Possible mechanisms of cancer prevention by nicotinamide. <i>British Journal of Pharmacology</i> , 2021, 178, 2034-2040.	2.7	10
40	Targeting Serine in Cancer: Is Two Better Than One?. <i>Trends in Cancer</i> , 2021, 7, 668-670.	3.8	10
41	NK cells beat T cells at early breast cancer control. <i>OncImmunity</i> , 2020, 9, 1806010.	2.1	8
42	The complement system is also important in immunogenic cell death. <i>Nature Reviews Immunology</i> , 2017, 17, 143-143.	10.6	6
43	Prevention of breast cancer by RANKL/RANK blockade. <i>Cell Research</i> , 2016, 26, 751-752.	5.7	5
44	MPA/DMBA-driven mammary carcinomas. <i>Methods in Cell Biology</i> , 2021, 163, 1-19.	0.5	5
45	Methods to Detect Immunogenic Cell Death In Vivo. <i>Methods in Molecular Biology</i> , 2020, 2055, 433-452.	0.4	5
46	Ketosis versus carbotoxicity â€“ metabolism determines the outcome of cancer immunotherapy. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1868266.	0.3	3
47	Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. <i>STAR Protocols</i> , 2021, 2, 100488.	0.5	3
48	Monitoring abscopal responses to radiation in mice. <i>Methods in Enzymology</i> , 2020, 635, 111-125.	0.4	2
49	Cytofluorometric assessment of cell cycle progression in irradiated cells. <i>Methods in Cell Biology</i> , 2022, , 1-16.	0.5	2
50	Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. <i>Clinical Cancer Research</i> , 2019, 25, 6890-6892.	3.2	0
51	Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. <i>Methods in Cell Biology</i> , 2021, 163, xvii-xxv.	0.5	0
52	Abstract PO-036: Immunological characterization of mouse HR+ mammary tumors relapsing after radiation therapy. , 2021, , .		0
53	Elderly patients and ovarian epithelial cancer (OEC) or primary peritoneal carcinoma (PPC): A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20718-e20718.	0.8	0
54	Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14712-e14712.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.. Journal of Clinical Oncology, 2015, 33, e19036-e19036.	0.8	0
56	Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 2016, 07, 455-463.	0.1	0
57	Nicotinamide drives T cell activation in the mammary tumor microenvironment. Journal of Translational Medicine, 2022, 20, .	1.8	0
58	Cytofluorometric assessment of acute cell death responses driven by radiation therapy. Methods in Cell Biology, 2022, , .	0.5	0
59	RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. Methods in Cell Biology, 2022, , .	0.5	0